8 results about "Apolipoprotein A1" patented technology

The present invention relates to a novel method of treating pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency (AATD), a genetic disorder that causes low levels of alpha-1 antitrypsin (AAT), a protein that protects the lungs from damage by neutrophil elastase. The invention consists of aerosolizing nanoparticles composed of apolipoprotein A1 enriched with AAT (A1NP). The invention aims to deliver these nanoparticles directly to the lungs, where they can interact with the alveolar surface and modulate the inflammatory and proteolytic processes that lead to emphysema. In particular, the inventors report that said nanoparticles are not cytotoxic, have anti-inflammatory and anti-elastase properties, can cross alveolar epithelial cells, and are not immunogenic in mice.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID Nos: 1-1313 and compositions, methods, and uses thereof.

The application belongs to the technical field of medical detection, and discloses a biomarker for diagnosing hepatocellular carcinoma and application thereof. The biomarker comprises a combination of coding nucleic acids of alpha-1-microglobulin, vitronectin, apolipoprotein A1, fibrinogen gamma chain, fibrinogen alpha chain and albumin; and the coding nucleic acids comprise mRNA or cDNA. The application purifies CD147 positive extracellular vesicles from plasma, and performs PCR detection on mRNA of hepatocellular carcinoma biomarkers carried in the extracellular vesicles. A HCC Score diagnosis model is constructed based on detection results of the biomarkers, and has high diagnostic sensitivity and specificity for hepatocellular carcinoma, has great potential in screening of early hepatocellular carcinoma, and has important practical significance for early diagnosis of hepatocellular carcinoma.

This invention belongs to the field of biotechnology, specifically relating to a complex peptide for enhancing animal immunity and its preparation method. The complex peptide is composed of InflamBlock-9 peptide and ImmunoEnhance-7 peptide in a mass ratio of 3:1. InflamBlock-9 peptide reduces the excessive secretion of pro-inflammatory factors IL-1β, IL-6, and TNF-α by targeting and inhibiting the key protein IκB kinase (IKK) in the NF-κB signaling pathway. ImmunoEnhance-7 peptide promotes the synthesis of immunoglobulins IgG, IgA, and apolipoprotein A1 (Apo-A1) by activating the JAK-STAT signaling pathway. The combined use of these two peptides significantly reduces the levels of IL-1β, IL-6, and SAA in cat serum under stress (P<0.05) and increases the levels of IL-10, IgG, and Apo-A1 (P<0.05 or P<0.10), effectively alleviating excessive inflammatory response and improving immunosuppression. The preparation method of this invention achieves efficient peptide preparation through a dual prokaryotic and eukaryotic expression system. The process is controllable and low-cost, making it suitable for the development of functional pet foods or health products.

The invention belongs to the technical field of biology, and particularly relates to a composite peptide capable of improving animal immunity and a preparation method of the composite peptide, and the composite peptide is formed by compounding InflamBlock-9 peptide and ImunoEnhance-7 peptide according to the mass ratio of 3: 1. Wherein the InflamBlock-9 peptide is used for reducing excessive secretion of proinflammatory factors IL-1beta, IL-6 and TNF-alpha through targeted inhibition of an NF-kappa B signal channel key protein Ikappa B kinase (IKK); the ImmunoEnhance-7 peptide is used for promoting the synthesis of immune globulins IgG (Immunoglobulin G) and IgA (Immunoglobulin A) and apolipoprotein A1 (Apo-A1) by activating a JAK-STAT (JavaScript Activated Amplification) signal channel. The combined use of the two can significantly reduce the levels (Plt, 0.05) of IL-1beta, IL-6 and SAA in the serum of cats in a stress state, improve the contents (Plt, 0.05 or Plt, 0.10) of IL-10, IgG and Apo-A1, and effectively relieve the inflammatory overexpression and improve the immunosuppression state. According to the preparation method, efficient preparation of the polypeptide is achieved through a prokaryotic and eukaryotic dual-expression system, the process is controllable, cost is low, and the preparation method is suitable for development of functional food or health care products for pets.

The application discloses a set of sepsis-specific biomarkers and application thereof, and belongs to the medical detection field.The marker is composed of the combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H.Through TMT proteomics screening of serum of clinical sepsis patients, seven core proteins, APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened out.Further screening of the seven proteins in a sepsis cell model and clinical sepsis patients obtains four more important proteins, APOA1, APOH, AMBP and SERPINC1.The four proteins are verified again in a sepsis mouse animal experiment and serum of clinical sepsis patients on a large scale, and the potential of the four core proteins as serum biomarkers for early diagnosis of sepsis is determined.

The invention discloses an apolipoprotein A1 fusion protein for preventing and treating atherosclerosis as well as a preparation method and application of the apolipoprotein A1 fusion protein, and belongs to the technical field of biological medicines. The method specifically comprises the following steps: cloning an apolipoprotein A1 gene to a pET28a expression vector, and transforming escherichia coli for expression; the expression product is purified, purification conditions are optimized, and the physicochemical properties of the expression product are represented by related means. In addition, the invention also relates to application of the fusion protein in the cellular level, including cytotoxicity experiment, and evaluation of protein uptake capability and cholesterol reverse transport capability of cells. Experimental results show that the prepared apolipoprotein A1 fusion protein can specifically target the liver, the atherosclerotic plaque area is remarkably reduced, and the apolipoprotein A1 fusion protein has important application potential in prevention and treatment of atherosclerosis.

The present application relates to the field of food and / or medicine technology, and discloses a hypolipidemic composition, a preparation method and application thereof.The hypolipidemic composition comprises Echium seed oil, Nigella seed oil and safflower seed oil.The present application uses specific natural substances, i.e.Echium seed oil, Nigella seed oil and safflower seed oil, as the functional components, and forms a natural composition which can significantly reduce total cholesterol and triglyceride and increase the content of serum apolipoprotein A1, and has obvious hypolipidemic effect, and can be applied to the development and preparation of hypolipidemic medicine and food, especially health food.